AEterna Zentaris Partner, Keryx Biopharmaceuticals, to Present Poster Highlighting Clinical Activity of Perifosine (KRX-0401) at
January 21 2010 - 8:35AM
PR Newswire (US)
Updated results from Phase 2 clinical trial of perifosine in
combination with capecitabine for the treatment of metastatic colon
cancer to be presented on Sunday, January 24, 2010 QUEBEC CITY,
Jan. 21 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (TSX: AEZ;
Nasdaq: AEZS), (the "Company"), a late-stage drug development
company specialized in oncology and endocrinology, today announced
that updated results from a Phase 2 clinical trial of perifosine
(KRX-0401) in combination with capecitabine conducted by its
partner and licensee for this compound in the United States, Canada
and Mexico, Keryx Biopharmaceuticals Inc. ("Keryx") (NASDAQ:KERX),
has been selected for poster presentation at the upcoming American
Society of Clinical Oncology ("ASCO") 2010 Gastrointestinal Cancers
Symposium, to be held in Orlando, Florida from January 22-24, 2010.
The clinical data to be presented demonstrates the potential safety
and efficacy of perifosine in the treatment of patients with
metastatic colon cancer. Details on the poster presentation are as
follows: Abstract #447 Title: "A Randomized phase II study of
perifosine in combination with capecitabine (P-CAP) versus
capecitabine plus placebo (CAP) in patients with second- or
third-line metastatic colon cancer (mCRC): updated results." Lead
Author: Johanna Bendell, MD Session Name: General Poster Session C:
Cancers of the Colon and Rectum Date: Sunday, January 24, 2010
Presentation Time: 7:00 AM- 8:00 AM; 12:00 NOON-1:00PM A copy of
the above referenced abstract can be viewed online through ASCO's
website, http://www.asco.org/. About AEterna Zentaris Inc. AEterna
Zentaris Inc. is a late-stage drug development company specialized
in oncology and endocrinology. News releases and additional
information are available at http://www.aezsinc.com/.
Forward-Looking Statements This press release contains
forward-looking statements made pursuant to the safe harbor
provisions of the U.S. Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the
availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability
of the Company to take advantage of business opportunities in the
pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. Investors
should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to
update these forward-looking statements. We disclaim any obligation
to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained
herein to reflect future results, events or developments except if
we are required by a governmental authority or applicable law.
DATASOURCE: AETERNA ZENTARIS INC. CONTACT: Investor Relations:
Dennis Turpin, SVP and CFO, (418) 652-8525 ext. 242, ; Media
Relations: Paul Burroughs, Director of Communications, (418)
652-8525 ext. 406,
Copyright